Owen Garrick, MD, MBA: Dr. Owen Garrick is a physician who has had a career focused on the research and finance sides of healthcare. He is President & COO of Bridge Clinical
Research, a contract research organization that focuses on several therapeutic areas and is dedicated to increasing minority representation among principal investigators participating in clinical trials. Dr. Garrick was formerly Director of Corporate Strategy and M&A at McKesson Corporation. Prior to McKesson, Dr. Garrick served as Executive Director and Co-Head of
Mergers & Acquisitions at Novartis Pharmaceuticals. Previously he spent four years at Goldman Sachs in New York, functioning as an investment advisor working with private healthcare companies as they sought to grow, raise capital, and perform initial public offerings. He has served as the President of the American Medical Association and was confirmed to the HHS
Secretary’s Advisory Committee on Human Research Protections from 2012-2016.
Faye Wattleton: Ms. Wattleton is Managing Director and Corporate Governance Practice Head at Alvarez & Marsal. She has developed an extraordinary track record of leadership as both a CEO of national nonprofit organizations and as a director of public and private corporations, academic institutions, and high-impact philanthropic organizations, including as chair of audit and corporate governance committees. Ms. Wattleton is a past member of the Board of Trustees of Columbia University, and currently serves on the Board of Governors of the Pardee Rand Graduate School, the Board of Directors of Jazz at Lincoln Center and the “I Have A Dream” Foundation. She is the 2004 recipient of the prestigious Fries Prize for service to improving public health, was inducted into the National Women’s Hall of Fame in 1993, and the single honoree for Ohio State University alumni medalist award for national and international career achievement.
“I am thrilled to welcome Ariel, Owen, and Faye to the Board of Trustees as we continue to navigate the challenges of guiding a prominent healthcare institution like NYBC,” said David Tendler, Chairman of the NYBC Board of Trustees. “These three professionals will add a tremendous amount of personal and industry expertise to our Board.”
About New York Blood Center
Founded in 1964, New York Blood Center (NYBC) is a nonprofit organization that is one of the largest independent, community-based blood centers in the world. NYBC, along with its partner organizations Community Blood Center of Kansas City, Missouri (CBC), and Innovative Blood Resources (IBR), based in St. Paul, Minnesota, collect approximately 3,500 units of blood products each day, serving local communities of more than 40 million people in New York, New Jersey, parts of Connecticut and Pennsylvania, the Kansas City metropolitan area, Minnesota, and Nebraska. NYBC and its partners also provide a wide array of transfusion-related medical services, including Comprehensive Cell Solutions, the National Center for Blood Group Genomics, the National Cord Blood Program, and the Lindsley F. Kimball Research Institute, which — among other milestones — developed the Hepatitis B vaccine and a patented solvent detergent plasma process innovating blood-purification technology worldwide.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-york-blood-center-announces-new-trustees-300473134.html
SOURCE New York Blood Center